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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the eDect of surgical interventions on postoperative visual and anatomical outcomes in people with a confirmed degenerative
lamellar macular hole.
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B A C K G R O U N D
Description of the condition
Lamellar macular holes (LMH) are small, partial-thickness defects
of the macula, which aDect 1.1% to 3.6% of the population, with a
preponderance towards people aged 50 to 70 years of age (Frisina
2019a).
Although LMHs can occur secondary to a variety of ophthalmic
disease processes, there are two forms of idiopathic LMHs that
have been recently distinguished based on their appearance,
associations, clinical course, and response to surgery: tractional
lamellar macular holes (TLMH) and degenerative lamellar macular
holes (DLMH; (Govetto 2016; Haritoglou 2019; Hubschman 2020)).
TLMHs are partial-thickness defects of the macula that are
associated with a classical type of contractile hyper-reflective
epiretinal membrane. They are oHen found with an intact ellipsoid
layer, and typical foveoschisis at the level of the Henle fibre layer,
which is sometimes associated with microcystoid spaces in the
inner nuclear layer and parafoveal retinal thickening, which can all
be visualised using ocular coherence tomography (OCT; (Figueroa
2019; Govetto 2016; Ko 2017; Pang 2015)). People aDected by
TLMHs tend to retain stable vision, without requiring intervention
(Figueroa 2019; Govetto 2016; Haritoglou 2019; Ko 2017; Pang
2015); however, when managed with pars plana vitrectomy, and
epiretinal membrane and internal limiting membrane peeling,
vision can improve significantly (Figueroa 2019).
In contrast, DLMHs are a newly defined, but long recognised
type of partial-thickness retinal defect with characteristic OCT
features, which include irregular central foveal thinning, and a
newly recognised type of epiretinal membrane, termed ‘lamellar
hole epiretinal proliferation’ (Morescalchi 2019). Lamellar hole
epiretinal proliferation diDers from typical epiretinal membrane;
it has a diDerent appearance, and seems to be non-contractile
(Morescalchi 2019). Although the exact pathogenesis of DLMHs is
unclear, Lamellar hole epiretinal proliferation is thought to develop
as a result of Müller cell-driven processes, which originate from
the middle retinal layers during the formation of LMHs (Govetto
2016; Haritoglou 2019; Morescalchi 2019; Pang 2015; Theodossiadis
2009). The influence of lamellar hole epiretinal proliferation on
the natural course of LMHs is unknown, and studies that have
investigated its potential contribution to the disease process
have produced contradictory results (dell'Omo 2017; Ko 2017;
Lai 2016). DLMHs may progressively worsen, and are associated
with outer retinal atrophy, a larger hole diameter, and disruption
to the ellipsoid zone, which contribute to poorer vision (Essex
2018; Govetto 2016; Jenisch 2017; Morescalchi 2019; Pang 2015;
Schumann 2015; Thompson 1996).
The exact pathophysiology underpinning the development of
DLMHs is unknown, however, their occurrence usually follow
posterior vitreous detachment, sometimes with the presence
of a pseudo-operculum on the posterior hyaloid face, which
suggests that partial avulsion of foveal tissue may be the causative
mechanism (Frisina 2019a; Johnson 2005). Evidence from OCT
scans suggests they may result from an abortive process of a full-
thickness macular hole, where the inner wall of the fovea, or a
superficial cyst becomes avulsed by traction from the vitreous, but
leaves suDicient tissue for the outer retinal layers (Theodossiadis
2009). Although the term 'degenerative' may suggest a slow and
progressive mechanism, leading to additional loss of retinal tissue,
this issue remains largely speculative.
The best method for managing people with LMHs (both TLMH
and DLMH) is unknown. Although the integrity of the external
limiting membrane seems important to improve visual function
(Govetto 2016), the expected functional and anatomical outcomes
following successful surgery remain unclear (Morescalchi 2019).
Previously published studies have been inconsistent in how they
define LMHs. Many do not diDerentiate DLMHs from TLMHs
according to current criteria, as they were published before
their development, and reported outcomes vary between studies
(Androudi 2009; Casparis 2011; Frisina 2019b; Garretson 2008;
Lee 2012). Therefore, comparing the eDectiveness of surgery to
manage LMHs has been diDicult. Some surgeons are concerned
that rather than improving outcomes, surgical intervention may
contribute to adverse outcomes, because it can be challenging to
separate the epimacular tissue from the DLMH’s internal limiting
membrane, which could create macular hole defects (Haritoglou
2019). Therefore, surgeons tend to manage people with LMHs
by observation to avoid potential surgery-related complications,
and because LMHs (particularly TLMHs) seem to have a relatively
stable anatomy, with largely unchanged visual function over time
(Govetto 2016; Nava 2017).
Few studies have compared surgical outcomes in people with
TLMHs and DLMHs (dell'Omo 2017; Figueroa 2019; Ko 2017;
Lai 2016). Figueroa and colleagues suggested that following
pars plana vitrectomy and internal limiting membrane peeling,
vision improved significantly more for tractional LMH or macular
pseudoholes than for DLMHs (Figueroa 2019). This may be because
DLMHs are associated with worse preoperative visual acuity, and
ellipsoid and external limiting membrane defects (dell'Omo 2017;
Ko 2017; Lai 2016; Nava 2017; Schumann 2015). However, Bottoni
and colleagues suggested that surgical intervention using pars
plana vitrectomy and internal limiting membrane peeling of all
perimacular membrane and lamellar hole epiretinal proliferation
may be an eDective treatment option for people with DLMH that
is associated with worsening retinal anatomy and visual function
(Bottoni 2013).
There may be a rationale to recommend surgical intervention
for people with DLMHs that show evidence of functional or
anatomical deterioration, or poor baseline vision that is causing
significant disability, to stabilise the DLMH and prevent further
visual deterioration.
Description of the intervention
Surgery is the most successful intervention for managing full-
thickness macular holes; roughly 95% achieve complete hole
closure following a single operation, and closure typically results
in improved vision (Kelly 1991; Spiteri Cornish 2013; Steel 2020).
Surgery usually involves pars plana vitrectomy and internal limiting
membrane peeling. This can close the hole by reducing retinal
compliance once the rigid internal limiting membrane is removed,
and moving the retina, which surrounds the hole, centripetally,
shortening the distance between the fovea and optic disc (Ishida
2014; Spiteri Cornish 2013; Steel 2020).
DLMHs have a more variable and unclear response to surgery
(dell'Omo 2017; Figueroa 2019; Ko 2017; Lai 2016; Schumann 2015).
Several published studies report improved postoperative visual
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function and retinal anatomy, some show no eDect, and some
highlight a potentially increased risk to developing complications,
such as secondary macular hole formation (dell'Omo 2017;
Figueroa 2019; Ko 2017; Lai 2016; Morescalchi 2019; Pang 2015;
Schumann 2015).
The most eDective surgical intervention to manage DLMHs is
unclear. A variety of diDerent surgical interventions have been
attempted (AAO 2019; Figueroa 2019; Frisina 2019b; Gaudric
2013; Schumann 2015; Shiode 2018; Shiraga 2013). Most involve
pars plana vitrectomy, with or without intravitreal tamponade
by instilling gas or air. The methods by which the lamellar
hole epiretinal proliferation and internal limiting membrane
are managed, in an attempt to achieve DLMH closure, are
of particular interest; some remove both the lamellar hole
epiretinal proliferation and internal limiting membrane (Figueroa
2019; Gaudric 2013), some spare the perifoveal internal limiting
membrane (Figueroa 2019), and others have incorporated novel
methodologies to achieve DLMH closure, such as epiretinal
membrane peel with inverted internal limiting membrane flap (AAO
2019), double inverted lamellar hole epiretinal proliferation with
internal limiting membrane flap (Frisina 2019b), by embedding
the lamellar hole epiretinal proliferation into the retinal cleavage
(Shiraga 2013), or by embedding the lamellar hole epiretinal
proliferation into the retinal cleavage, combined with internal
limiting membrane inversion (Shiode 2018).
How the intervention might work
The mechanisms by which peeling the internal limiting membrane,
or lamellar hole epiretinal proliferation, or both, encourages DLMH
closure is not clear, especially, because lamellar hole epiretinal
proliferation causes minimal contraction, so mechanisms that
close macular holes are unlikely to play such a significant
role in postoperative outcomes (Govetto 2016; Haritoglou 2019;
Morescalchi 2019; Pang 2015; Theodossiadis 2009). Theories
include: by inlaying the lamellar hole epiretinal proliferation
and the internal limiting membrane, cytokines may be released
and glial cells activated, to encourage normal healing processes;
lamellar hole epiretinal proliferation may be an aberrant healing
response, so, once removed by peeling, may help to restore
the normal retinal anatomy; and finally, although lamellar hole
epiretinal proliferation has less contractile characteristics than
other epiretinal membranes, there is oHen a component of typical
epiretinal membrane present, so epiretinal membrane and internal
limiting membrane removal may improve retinal compliance and
restore the anatomical integrity of the retina.
Why it is important to do this review
This Cochrane Review aims to synthesise current evidence,
obtained from randomised controlled trials to determine the eDect
of surgical intervention on postoperative functional (e.g. visual
function) and anatomical (e.g. central retinal thickness) outcomes
for people aDected by DLMHs.
This topic is important because DLMHs can progress over time, and
are associated with deteriorating visual function, however, we do
not understand the most appropriate way to manage these patients
(Haritoglou 2019). A conservative approach is most commonly
adopted by clinicians because of concerns related to intraoperative
and postoperative adverse events; on the other hand, delaying
intervention may, unnecessary, risk visual disability (Pang 2015).
This review will improve our understanding of the value of surgery
in managing DLMHs, and either inform future clinical practices, or
suggest the most appropriate investigative approaches required for
future research.
O B J E C T I V E S
To assess the eDect of surgical interventions on postoperative
visual and anatomical outcomes  in people with a confirmed
degenerative lamellar macular hole.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCT) only  in this
review. Study status will not aDect study inclusion.
Types of participants
The following criteria will determine inclusion:
• Studies involving participants with a confirmed diagnosis of
degenerative lamellar macular hole (DLMH), evidenced on
ocular coherence tomography (OCT; (Hubschman 2020)). For a
confirmed diagnosis to be made, the following criteria must be
fulfilled:
• a defect with irregular foveal inner surface contours;
• presence of epiretinal proliferation;
• no full-thickness defect in the macula.
The following criteria will determine participant exclusion:
• non-degenerative lamellar macular holes (e.g. tractional,
secondary, non-specified or unclear diagnosis);
• other diseases that can mimic foveal disease (e.g. macular
telangiectasia (MacTel));
• significant comorbid ocular pathology (e.g. visually significant
cataract, age-related macular degeneration, glaucoma, diabetic
retinopathy, or retinal vascular diseases);
• previous vitrectomy.
No restrictions will be made based on geographical location, the
study setting, or participant-specific characteristics (e.g. age and
sex).
Types of interventions
We will consider studies that involve one or more surgical
intervention(s), alone or in combination, in at least one arm of a
RCT for inclusion. Surgical interventions can include pars plana
vitrectomy and:
• detachment and removal of the posterior hyaloid;
• peeling of the internal limiting membrane;
• peeling of epiretinal tissues (either classic epiretinal membrane
or lamellar hole epiretinal proliferation);
• inlay or creation of a flap of lamellar hole epiretinal proliferation
or internal limiting membrane;
• foveal-sparing internal limiting membrane peel;
• filling of the vitreous cavity with gas or air.
Surgical interventions for degenerative lamellar macular holes (Protocol)
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The control arm of the RCT can include at least one (or any
combination) of the following:




Types of outcome measures
We will not exclude studies on the basis of reporting of outcomes.
We plan to collect data on change between preoperative and
postoperative measurements. If data are only reported as a final
value, we will collect these data and include them in statistical
analyses. If an outcome is reported both as change and final value,
we will preferentially use values describing the change before and
aHer an intervention.
Primary outcomes
Change in BCVA from baseline (before surgery) to 6-month follow-up
We will collect data detailing BCVA, regardless of the measurement
chart used (e.g. logMAR, Early Treatment Diabetic Retinopathy
Study (ETDRS) letters, Snellen measures). We will only pool data if
measurements can be converted to a logMAR score.
We will consider a 0.2 logMAR change in vision as clinically
significant.
Secondary outcomes
Secondary outcome measures will be divided into the following
three categories.
1. Functional outcomes
• change in BCVA from baseline to 3-month or 12-month follow-
up, or both.
• the length of time to reach driving-standard vision from
baseline.
• change in the extent of metamorphopsia experienced by
participants from baseline to 3-month, 6-month, or 12-month
follow-up, or a combination. Metamorphopsia can be assessed
using any validated methodology, such as the D chart, M chart,
and patient-reported measures (McGowan 2016; Patel 2019;
Wada 2017).
• change in retinal sensitivity (in decibels)  in participants from
baseline to  3-month, 6-month, or 12-month follow-up, or a
combination. Retinal sensitivity can be measured using any
validated methodology, such as microperimetry or visual fields
(Donati 2019; Kim 2014; Laishram 2017).
2. Anatomical outcomes
• change in central retinal thickness (CRT; in microns)  from
baseline to 3-month, 6-month, 12-month follow-up, or a
combination. We will consider a 50 micron change as clinically
significant.
• change in ellipsoid and external limiting membrane defects
from baseline to 3-month, 6-month, 12-month follow-up, or a
combination. We will consider a 50 micron change as clinically
significant.
• changes recorded in outer retinal thickness at the fovea (in
microns) from baseline to 3-month, 6-month, 12-month follow-
up, or a combination
3. Participant-specific outcomes
• vision-reported quality of life (VRQOL) at 3-month, 6-month, 12-
month follow-up, or a combination, using any validated tool.
Adverse e;ects
• we will compare the frequency of all complications between all
study arms, regardless of the intervention.
When a surgical intervention is performed in at least one
study arm, we will present the frequency of intraoperative
complications.  In trials with two surgical arms, we will analyse
and compare complications, based on the CONSORT extension
for harm criteria guidelines and consensus documents (Ioannidis
2004; Moher 2010). Early postoperative complications are defined
as those occurring within one-month follow-up, late postoperative
complications, as those occurring aHer one-month follow-
up. Examples of postoperative complications include: reduced
vision (> 0.2  logMAR), cataract formation, retinal detachment,
endophthalmitis, vitreous haemorrhage, and the formation of
surgically-induced macular holes.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search the
following electronic databases for randomised controlled trials and
controlled clinical trials. There will be no restrictions to language or
year of publication.
• Cochrane Central Register of Controlled Trials (CENTRAL; which
contains the Cochrane Eyes and Vision Trials Register) in the
Cochrane Library (latest issue; Appendix 1);
• MEDLINE Ovid (1946 to present; Appendix 2);
• Embase Ovid (1980 to present; Appendix 3);
• Scopus SciVerse (1970 to present; Appendix 4);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
Appendix 5);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; Appendix 6);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP; www.who.int/ictrp; Appendix 7).
Searching other resources
We will search the reference lists of included trials to identify
any other eligible trials or relevant systematic reviews and meta-
analyses which our search strategy may miss.
If full texts are unavailable, we will contact the corresponding
author directly, by email, or telephone, or both, and request the full
text of the published article. If, aHer one month, the corresponding
author has not provided the full text, we will exclude the study and
document the reason for exclusion.
Surgical interventions for degenerative lamellar macular holes (Protocol)
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Data collection and analysis
Selection of studies
Two review authors (DCM and DHS) will assess all titles and
abstracts retrieved from the search strategy to determine their
eligibility for inclusion in the review, based on predefined inclusion
and exclusion criteria, using an online review management
soHware (Covidence). Following the initial assessment, we will
obtain the full text of studies that show potential for inclusion, and
the same two review authors will independently review them. If
there are disagreements about which studies are eligible, they will
consult a third review author (JR), until we reach consensus. We will
specify the reasons for exclusion. We will summarise the details of
this process and the reasons for article exclusion in a flow chart,
designed in accordance with the PRISMA statement (Liberati 2009).
For potentially eligible studies identified on trials registers, we
will contact the chief investigator of the trial directly, by email or
telephone, or both, to request the published data if the study has
a recorded expected completion date of more than two years in
the past. We will document the study as ongoing if its expected
completion date is within two years in the past, or is in the future.
Data extraction and management
We will use a data extraction sheet to extract information from
included studies and to summarise their details. Two review
authors (DCM and DHS) will trial the sheet on the first two
eligible articles, to ensure it is robust, and to make any necessary
amendments before they review all of the articles. If data appear to
be missing from the published article of a trial, we will contact the
corresponding author directly, by email or telephone, or both, and
request the data.
We will collect and record outcome data in Review Manager 5
(Review Manager 2014). We will extract data from the included
studies on the following variables (Table 1).
• Primary author
• Title
• Country where the study was conducted
• Healthcare setting
• Sources of funding
• Potential author conflicts of interest
• Publication status
• Year article was published
• Study-specific eligibility criteria
• RCT trial design (e.g. parallel group, within-person, cluster,
cross-over)
• Randomisation timing (the point at which participants were
randomised into diDerent arms)
• Randomisation method (e.g. simple randomisation, block
randomisation, stratified randomisation)
• Number of participants randomised to each arm
• Number of participants per arm included in the statistical
analysis
• Number of participants lost per group and reasons explained
(e.g. lost to follow-up, removal of consent following initial
enrolment)
• Baseline participant data (e.g. BCVA, metamorphopsia, phakic
status, OCT measurements)
• Type of intervention(s) in each RCT arm
• Trial outcomes with definitions: primary outcomes, secondary
outcomes, and adverse outcomes
• Outcome comparisons by group: primary, secondary, and
adverse outcomes
• Confounding variables (e.g. phakic status)
• Sources of bias (e.g. masking)
• Quality of evidence (in accordance with GRADE approach
Schünemann 2013)
Outcome data
For trials with multiple arms, we will only collect data relating to the
interventions outlined in our predefined eligibility criteria.
Assessment of risk of bias in included studies
Two review authors (DCM and DHS) will independently assess the
risk of bias in each included RCT, referring to Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions version
6 (Higgins 2011). They will review each study according to the
six domains detailed in the assessment tool. They will specifically
evaluate the completeness of data and the extent of masking
(blinding). The extent of bias in selection, performance, detection,
attrition and outcome reporting will all be assessed (Higgins 2011).
Following thorough evaluation, we will grade each domain as low
risk of bias, high risk of bias or unclear risk of bias. When the extent
of bias is unclear, we will contact the chief investigator of ongoing
trials or the corresponding author of published trials by email or
telephone or both to obtain the information necessary to inform an
accurate assessment.
Measures of treatment e;ect
We will report risk ratios (RR) with 95% confidence intervals (CI) for
dichotomous variables. Where possible, we will assess whether or
not continuous data are skewed (Altman 1996). We will compare
normally distributed continuous data using the mean diDerence
(MD) with 95% CIs. TIme-to-event data will be analysed using the
hazard ratio. We may need to calculate the hazard ratio using data
on observed and expected events, depending on how the data are
reported in the studies.
We will collect data detailing BCVA, regardless of the measurement
chart used (e.g. logMAR, ETDRS letters, Snellen measures). We will
only pool data if measurements can be converted to logMAR score.
For continuous variables measured on diDerent scales, we will use
standard mean diDerence (SMD) for comparisons. The size of an
eDect relative to its variability can be expressed using SMD. For
scales that point in opposite directions (one increases, another
decreases), we will mathematically manipulate the data to ensure
that all scales point in the same direction.
Unit of analysis issues
The eye with a DLMH will be considered the unit of analysis, rather
than the individual participant. Included studies may randomise to
one or both eyes.
If participants show evidence of DLMHs in both eyes, both will be
included and reported in the review.
Surgical interventions for degenerative lamellar macular holes (Protocol)
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If the trial randomised by participant and included both eyes, each
receiving the same intervention, we will consider that outcomes in
both eyes are likely to be similar. We will analyse as 'clustered data',
and make adjustments for within-person correlations.
If the trial randomised according to each individual eye, we will
analyse the data as paired data.
If there is uncertainty about the methodology used for selection, we
will contact the corresponding trial investigator or corresponding
author and ask for clarification.
In participants with both eyes aDected, we will review the
interventions performed per eye in detail, to determine if a
confounding cross-over eDect may be possible. This is unlikely for
surgical interventions, but may occur in those undergoing non-
surgical therapies.
Dealing with missing data
We expect that some trial reports will contain missing data because
it is a common scenario in clinical trials (Dziura 2013). We will
determine the reasons for participant exclusion and loss to follow-
up aHer randomisation because they may introduce bias into the
trial. Where data that are important for the analysis are missing,
we will contact the study’s corresponding author and request the
data. Where possible, we will perform an intention-to-treat (ITT)
analysis, using imputed data completed by the trial investigator.
However, we will not impute missing data ourselves. If ITT analysis
is not possible, we will perform a complete  case analysis, based
on the assumption that data are missing at random. We will assess
how reasonable this assumption is for each included trial, based
on factors such as exclusion criteria, and the extent to which
participants are lost to follow-up.
Assessment of heterogeneity
We will perform a thorough assessment of heterogeneity,
using a multi-faceted approach. We will assess heterogeneity
secondary to methodological and clinical variability by evaluating
the characteristics of each trial. We will assess participant
characteristics and the interventions performed in each study. This
will inform the extent to which studies can be considered similar,
so results can be sensibly pooled for analysis (Higgins 2002). We
will calculate the I2, an estimate of the percentage of variability
in eDect sizes arising from trial heterogeneity rather than chance,
to summarise heterogeneity in included RCTs (Higgins 2002). We
will consider that I2 values less than 25% indicate a low level of
heterogeneity, over 50% indicates substantial heterogeneity, and
75% indicates very high heterogeneity (Higgins 2002).
We will use the Chi2 test to assess statistical heterogeneity; a P value
< 0.010 will indicate statistically significant heterogeneity. Where
high risk of heterogeneity is evident, we will explore the underlying
causes. We will use forest plots to determine how consistent results
are in diDerent studies, including the direction and size of eDects
(Schünemann 2008).
Assessment of reporting biases
Biases in reporting can occur when results are presented in a
particular format to influence research findings. Publication bias is
an example, one in which the outcomes of a study influence the
probability that a finding is published. One consequence of this is
reported eDects of an intervention may be larger in smaller-sized
RCTs than in larger studies (Joober 2012).
Estimates of individual studies according to their study size
and subsequent precision of their reported findings can be
diagrammatically represented by a funnel plot (Sterne 2011). If we
include a suDicient number of studies (N = 10), we will construct
funnel plots. Asymmetry in such a funnel plot may indicate small
study eDects and potential publication bias.
The risk of selective outcome reporting will be assessed as part of
the risk of bias assessment tool detailed above (Higgins 2011).
Data synthesis
We will pool data using a random-eDects model in Review
Manager 5 (Review Manager 2014). If there are fewer than three
trials in a comparison, we will use a fixed-eDect model, because
it provides a more robust estimate of eDect when there are
limited data available, compared with a random-eDects model.
If inconsistencies between individual study results are significant
enough to render a pooled result an inappropriate method to
summarise individual trial results (e.g. I2 > 50% and P < 0.10), we
will describe the pattern of the individual trial results instead.
If we find statistical heterogeneity, but all eDect estimates are in
the same direction so that a pooled estimate would be appropriate,
we may report trial results as pooled data.  If it is not possible
to perform a meta-analysis, due to clinical or methodological
heterogeneity, we will combine the details of included studies in
a narrative synthesis, according to the type of comparator and
outcome measures.
Subgroup analysis and investigation of heterogeneity
If we find heterogeneity, and there are enough trials available, we
will analyse the eDect of the interventions according to specific
subgroups. Subgroups will include age, the presence of a classic
epiretinal membrane, and the presence of an external limiting
membrane defect.
Sensitivity analysis
Sensitivity analysis allows one to assess the robustness of results
aHer considering the inclusion of trials at high risk of bias, and
examining the eDects of using fixed-eDect and random-eDects
models.
If possible, we will perform a sensitivity analysis to examine the
eDects of masking, the methods used to randomise participants,
concealment of allocation groups, the use of fixed-eDect and
random-eDects models, and attrition bias. Once we have collected
the details of the specific characteristics of individual trials, we may
consider additional sensitivity analyses, depending on our review
of the data.
Summary of findings and assessment of the certainty of the
evidence
Two review authors (DCM and DHS) will use the GRADE approach to
independently examine and classify the certainty of the evidence
for each outcome as high, moderate, low, or very low (Schünemann
2013). If disagreements between the two review authors occur, they
will consult the third review author (JR); discussions between all
three review authors will reach consensus.
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We will present the most important outcomes in a separate
'Summary of findings' table for each comparison. The tables
will include information about the magnitudes of relative and
absolute eDects of the interventions examined, the available
evidence and the quality of the evidence (Schünemann 2019a).
Quality of evidence will be based on five domains: risk of
bias, inconsistency, indirectness, imprecision and publication bias
(Schünemann 2019b). We will include the following outcomes in
each table:
• change in BCVA from baseline to 6-month follow-up;
• change in metamorphopsia from baseline to 6-month follow-up;
• change in anatomical outcomes (CRT, ellipsoid and external
limiting membrane defects, and outer retinal thickness at the
fovea) from baseline to 6-month follow-up based on information
obtained from OCT;
• vision-related quality of life; and
• adverse outcomes.
These outcomes are considered  most important because they
detail key patient-specific information about vision, quality of
life and  adverse outcomes. Outcomes which detail anatomical
changes are also important because diDerences in outer retinal
anatomy may improve our understanding of how DLMHs form and
the mechanisms at play following surgical interventions. 
We will develop a separate 'Summary of findings' table for the
following comparisons:
Primary comparison:
• surgery (of any type) versus observation;
Secondary comparisons
• surgery with peri-DLMH internal limiting membrane peel and/or
LMEP preservation versus complete internal limiting membrane
peeling, and;
• surgery with peeling of any type versus surgery with adjuvants
(e.g. platelets, blood etc.).
For the comparison 'surgery (of any type)', all surgical interventions
will be pooled.   Similarly, 'surgery with peeling of any type' will
be derived by combining all surgical interventions which have
involved an intra-operative membrane peel.
A C K N O W L E D G E M E N T S
Cochrane Eyes and Vision (CEV) will create and execute the
electronic search strategies. We thank Clemens Lange and Abdul
Shakoor for peer reviewing this protocol and Noemi Lois, Jennifer
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A D D I T I O N A L   T A B L E S
 
Mandatory items   Optional items
Methods
Study design • Parallel-group RCT i.e. people randomised to treatment
• Within-person RCT i.e. eyes randomised to treatment
• Cluster-RCT i.e. communities randomised to treatment
• Cross-over RCT
Reasons for no fol-
low-up: exclusions
after randomisa-




how missing data was
handled. Evidence of
Table 1.   Study characteristics 
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Eyes or Unit of ran-
domisation/unit of
analysis
• One eye included in study: the eye showing evidence of a DLMH as defined by
inclusion criteria
• Two eyes included in study, both eyes received same treatment: both must
show evidence of DLMH and treatment received should be randomised using
with individual eyes as units of randomisation/analysis
• Two eyes included in study, eyes received different treatments: both must
show evidence of DLMH and treatment received should be randomised
 
Participants




Total number of par-
ticipants
Information collected to describe the participants should have been collected for
the total number initially enrolled in the study, not only for those who were fully
followed-up.
 
Number (%) of men
and women
   
Average age and age
range
   
Inclusion criteria As specified in inclusion and exclusion criteria section of protocol  
Exclusion criteria As specified in inclusion and exclusion criteria section of protocol  
Interventions
Intervention (N = )
Comparator (N = )
• Number of people randomised to each group
• Name of surgical or non-surgical intervention





defined in study re-
ports
• Any or all specified primary, secondary, or adverse outcomes reported (Y/N);




Date conducted Specify dates of recruitment of participants mm/yr to mm/yr Full study name: (if
applicable) Reported
subgroup analyses (Y/
N) Were trial investiga-
tors contacted?
Table 1.   Study characteristics  (Continued)
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As reported in published articles. If not published, will be requested from chief in-
vestigator of trial.
 
Included in trials reg-
istry
Y/N, including registration number if available  
Table 1.   Study characteristics  (Continued)
DLMH: deep lamellar macular hole
 
 
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 degenerative near/2 lamellar
#2 lamellar near/2 (macula* or hole*)
#3 macular lamellar hole*
#4 partial thickness near/2 (macula* or hole*)
#5 DLMH* or LMH* or PTMH* or PTH*
#6 pseudohole*
#7 fovea* near/2 defect*
#8 non near/1 full near/1 thick* near/1 macula*
#9 (atypical or dens*) near/2 ERM*
#10 (atypical or dens*) near/2 epiretinal membrane
#11 AERM
#12 degenerative adj2 (membrane or epiretinal or ERM*)
#13 (epiretinal or ERM*) near/5 macula* pigment*
#14 epiretinal proliferation
#15LHEP
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Vitrectomy] this term only
#18 PPV*
#19 vitrectom*
#20 cortical near/2 vitreous
#21 MeSH descriptor: [Epiretinal Membrane] this term only
#22 internal near/2 limit* near/2 membrane*
#23 ILM or FSILM
#24 fovea* near/2 spar*
#25 peel* or inlay or flap or flap
#26 MeSH descriptor: [Endotamponade] this term only
#27 gas or air
#28 tamponade*





#34 SF6 or C2F6 or C3F8
#35 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
#36 #16 and #35
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
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11. 9 not (9 and 10)
12. 8 not 11
13. (degenerative adj2 lamellar).tw.
14. (lamellar adj2 (macula$ or hole$)).tw.
15. macular lamellar hole$.tw.
16. (partial thickness adj2 (macula$ or hole$)).tw.
17. (DLMH$ or LMH$ or PTMH$ or PTH$).tw.
18. pseudohole$.tw.
19. (fovea* adj2 defect$).tw.
20. (non adj1 full adj1 thick$ adj1 macula$).tw.
21. ((atypical or dens$) adj2 ERM$).tw.
22. ((atypical or dens$) adj2 epiretinal membrane).tw.
23. AERM.tw.
24. (degenerative adj2 (membrane or epiretinal or ERM$)).tw.







32. (cortical adj2 vitreous).tw.
33. Epiretinal Membrane/
34. (internal adj2 limit$ adj2 membrane$).tw.
35. (ILM or FSILM).tw.
36. (fovea* adj2 spar$).tw.
37. (peel$ or inlay or flap or flaps).tw.
38. Endotamponade/
39. (gas or air).tw.
40. tamponade$.tw.





46. (SF6 or C2F6 or C3F8).tw.
47. or/29-46
48. 28 and 47
49. 12 and 48
50. (hyperparathyroidism or parathyroid$ or hydrocephalus or hemodialysis).ti.
51. 49 not 50
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
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11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. (degenerative adj2 lamellar).tw.
34. (lamellar adj2 (macula$ or hole$)).tw.
35. macular lamellar hole$.tw.
36. (partial thickness adj2 (macula$ or hole$)).tw.
37. (DLMH$ or LMH$ or PTMH$ or PTH$).tw.
38. pseudohole$.tw.
39. (fovea* adj2 defect$).tw.
40. (non adj1 full adj1 thick$ adj1 macula$).tw.
41. ((atypical or dens$) adj2 ERM$).tw.
42. ((atypical or dens$) adj2 epiretinal membrane).tw.
43. AERM.tw.
44. (degenerative adj2 (membrane or epiretinal or ERM$)).tw.





50. pars plana vitrectomy/
51. PPV$.tw.
52. vitrectom$.tw.
53. (cortical adj2 vitreous).tw.
54. epiretinal membrane/
55. (internal adj2 limit$ adj2 membrane$).tw.
56. (ILM or FSILM).tw.
57. (fovea* adj2 spar$).tw.
58. (peel$ or inlay or flap or flaps).tw.
59. endotamponade/







67. (SF6 or C2F6 or C3F8).tw.
68. or/49-66
69. 48 and 68
70. 32 and 69
71. (hyperparathyroidism or parathyroid$ or hydrocephalus or hemodialysis).ti.
72. 70 not 71
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Appendix 4. Scopus SciVerse search strategy
( ( TITLE-ABS-KEY ( lamellar W/2 macular W/2 holes ) ) OR ( degenerative W/2 lamellar ) ) AND ( random )
Appendix 5. ISRCTN search strategy
" lamellar macular hole"
"degenerative lamellar"
Appendix 6. ClinicalTrials.gov search strategy
lamellar macular hole
degenerative lamellar
Appendix 7. WHO ICTRP search strategy
lamellar macular hole
degenerative lamellar
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